VIR
Vir Biotechnology, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+67/100
Last price
11.60
▼ 0.18 (1.53%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
11.78
Day high
11.90
Day low
11.26
Volume
2.59M
Market cap
$1.96B
P/E (TTM)
—
52W range
4.82 – 11.94
Trailing performance
Returnvs SPY
1W
+8.92%
+7.0%
1M
+1.89%
+0.7%
3M
+11.22%
+6.7%
6M
+26.50%
+8.3%
YTD
+92.37%
+78.1%
1Y
+102.44%
+86.0%
3Y
+23.80%
-58.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VIR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+38.42K
Net buying
Buy transactions
7
64.00K shares
Sell transactions
3
25.58K shares
Net transactions
+10
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
11.12M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | COUGHLIN TIMOTHY Director |
STOCK | 16.00K | $0 | Direct |
| Jun 1, 26 | NAPOLITANO JANET ANN Director |
SELL | 3.20K | $30.24K | Direct |
| Jun 1, 26 | SABATINI BRENT Officer |
SELL | 379 | $3.58K | Direct |
| May 27, 26 | SIGAL CHARLES ELLIOTT Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | BISCHOFBERGER NORBERT W Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | MORE ROBERT J Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | HATFIELD JEFFREY S Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | RAMY SAMIR FARID PH.D. Director |
STOCK | 8.00K | $0 | Direct |
| May 27, 26 | NAPOLITANO JANET ANN Director |
STOCK | 8.00K | $0 | Direct |
| May 1, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $221.03K | Direct |
| Apr 6, 26 | DE BACKER MARIANNE Chief Executive Officer |
SELL | 72.56K | $664.35K | Direct |
| Apr 1, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $199.62K | Direct |
| Mar 23, 26 | SABATINI BRENT Officer |
SELL | 7.71K | $70.32K | Direct |
| Mar 2, 26 | SATO VICKI LEE Director |
SELL | 22.00K | $209.18K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DE BACKER MARIANNE |
Chief Executive Officer | 1.00M | Sale |
DE VERNEUIL VANINA ALEXANDRA HUARD |
General Counsel | 112.98K | Sale |
EISNER MARK E |
Officer | 154.02K | Sale |
HANLY ANN M |
Chief Technology Officer | 117.90K | Sale |
MORE ROBERT J |
Director | 558.57K | Stock Award(Grant) |
O'BYRNE JASON |
Chief Financial Officer | 162.62K | Sale |
SABATINI BRENT |
Officer | 61.90K | Sale |
SATO VICKI LEE |
Director | 1.08M | Sale |
SCANGOS GEORGE A |
Director | 3.81M | Sale |
SVF ENDURANCE CAYMAN LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
Fundamentals
Market cap$1.96B
Enterprise value$1.52B
Revenue (TTM)$303.23M
Gross profit$-180.08M
EBITDA$-267.96M
Net income$-251.68M
EPS (TTM)$-1.76
Free cash flow$-38.89M
Total cash$532.73M
Total debt$93.27M
Book value / share$5.04
Shares outstanding169.22M
Float129.82M
Short % of float11.76%
Dividend yield0.00%
Beta (5Y)1.59
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.66
PEG ratio—
Price / sales—
Price / book2.30
EV / revenue5.02
EV / EBITDA-5.69
Gross margin-59.39%
Operating margin30.75%
Profit margin-83.00%
Return on equity-26.08%
Return on assets-14.51%
Debt / equity9.49
Current ratio6.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $66.52M | $63.71M | $39.49M | $1.58B | +4.4% |
| Operating revenue | $63.13M | $61.37M | $37.38M | $1.58B | +2.9% |
| Cost of revenue | $26.00K | $845.00K | $2.77M | $146.32M | -96.9% |
| Gross profit | $66.49M | $62.87M | $36.73M | $1.43B | +5.8% |
| Research & development | $455.97M | $506.50M | $579.72M | $474.65M | -10.0% |
| Selling, general & admin | $92.07M | $119.03M | $174.44M | $161.76M | -22.6% |
| Total operating expense | $546.00M | $615.04M | $707.48M | $601.09M | -11.2% |
| Operating income | -$479.51M | -$552.17M | -$670.75M | $833.07M | +13.2% |
| Net interest income | $40.24M | $71.81M | $86.99M | $28.09M | -44.0% |
| Pre-tax income | -$437.77M | -$523.11M | -$628.19M | $754.28M | +16.3% |
| Tax provision | $217.00K | -$1.15M | -$13.08M | $238.44M | +119.0% |
| Net income | -$437.99M | -$521.96M | -$615.06M | $515.84M | +16.1% |
| Net income to common | -$437.99M | -$521.96M | -$615.06M | $515.84M | +16.1% |
| Basic EPS | -3.16 | -3.83 | -4.59 | 3.89 | +17.5% |
| Diluted EPS | -3.16 | -3.83 | -4.59 | 3.83 | +17.5% |
| EBIT | -$479.51M | -$552.17M | -$670.75M | $833.07M | +13.2% |
| EBITDA | -$467.83M | -$537.61M | -$651.29M | $839.85M | +13.0% |
| Basic shares | 138.52M | 136.25M | 134.13M | 132.61M | +1.7% |
| Diluted shares | 138.52M | 136.25M | 134.13M | 134.81M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $232.19M | $222.95M | $241.58M | $848.63M | +4.1% |
| Cash & short-term investments | $467.01M | $905.35M | $1.52B | $2.40B | -48.4% |
| Total current assets | $514.08M | $1.04B | $1.59B | $2.52B | -50.7% |
| Property, plant & equipment | $117.72M | $122.86M | $167.20M | $188.17M | -4.2% |
| Goodwill & intangibles | $24.79M | $25.06M | $39.53M | $49.66M | -1.1% |
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | -28.3% |
| Total current liabilities | $92.81M | $119.66M | $175.41M | $511.03M | -22.4% |
| Total debt | $97.85M | $97.89M | $124.54M | $127.97M | -0.0% |
| Total liabilities | $237.55M | $248.43M | $328.82M | $724.13M | -4.4% |
| Retained earnings | -$1.20B | -$759.78M | -$237.82M | $377.24M | -57.6% |
| Shareholder equity | $765.28M | $1.15B | $1.59B | $2.08B | -33.5% |
| Working capital | $421.26M | $922.80M | $1.41B | $2.01B | -54.3% |
| Net tangible assets | $740.49M | $1.13B | $1.55B | $2.03B | -34.2% |
| Shares issued | 139.47M | 136.96M | 134.78M | 133.24M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$437.99M | -$521.96M | -$615.12M | $515.84M | — | +16.1% |
| Depreciation & amortisation | $11.68M | $14.56M | $19.45M | $6.78M | — | -19.8% |
| Stock-based compensation | $49.07M | $78.46M | $111.32M | $102.08M | — | -37.5% |
| Change in working capital | -$22.45M | -$83.32M | -$332.71M | $665.37M | — | +73.1% |
| Operating cash flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | — | +12.2% |
| Capital expenditure | -$4.83M | -$7.30M | -$21.57M | -$68.01M | — | +33.8% |
| Investing cash flow | $310.37M | $499.37M | $164.63M | -$1.19B | — | -37.8% |
| Share buybacks | — | — | — | — | $0 | — |
| Financing cash flow | $3.79M | $4.39M | $7.48M | $34.76M | — | -13.7% |
| Free cash flow | -$396.61M | -$453.65M | -$800.36M | $1.60B | — | +12.6% |
| End cash position | $241.07M | $318.69M | $261.29M | $867.97M | — | -24.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $238.94M | -$41.00K | $63.76M | -$65.00K | $1.03M | — | +582,868.3% |
| Operating revenue | $238.94M | -$41.00K | $60.37M | -$65.00K | -$495.00K | — | +582,868.3% |
| Cost of revenue | $0 | — | $26.00K | -$11.00K | $11.00K | $0 | — |
| Gross profit | $238.94M | — | $63.73M | -$54.00K | $1.02M | $1.79M | — |
| Research & development | $135.28M | $108.92M | $88.35M | $151.46M | $97.51M | — | +24.2% |
| Selling, general & admin | $30.20M | $23.34M | $23.62M | $22.23M | $22.28M | — | +29.4% |
| Total operating expense | $165.47M | $132.25M | $111.66M | $173.39M | $119.61M | — | +25.1% |
| Operating income | $73.47M | -$132.29M | -$47.92M | -$173.44M | -$118.59M | — | +155.5% |
| Net interest income | $8.97M | $7.19M | $7.80M | $9.36M | $10.79M | — | +24.7% |
| Pre-tax income | $80.26M | -$125.53M | -$43.06M | -$162.97M | -$110.79M | — | +163.9% |
| Tax provision | $179.00K | $170.00K | -$137.00K | $168.00K | $170.00K | — | +5.3% |
| Net income | $80.08M | -$125.69M | -$42.92M | -$163.14M | -$110.96M | — | +163.7% |
| Net income to common | $80.08M | -$125.69M | -$42.92M | -$163.14M | -$110.96M | — | +163.7% |
| Basic EPS | 0.48 | -0.85 | -0.31 | -1.17 | -0.80 | — | +156.5% |
| Diluted EPS | 0.47 | -0.85 | -0.31 | -1.17 | -0.80 | — | +155.3% |
| EBIT | $73.47M | -$132.29M | -$47.92M | -$173.44M | -$118.59M | — | +155.5% |
| EBITDA | $76.27M | -$129.48M | -$45.02M | -$170.44M | -$115.67M | — | +158.9% |
| Basic shares | 167.72M | 147.36M | 139.23M | 138.93M | 138.45M | — | +13.8% |
| Diluted shares | 168.88M | 147.36M | 139.23M | 138.93M | 138.45M | — | +14.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $278.73M | $274.16M | $232.19M | $170.08M | $211.10M | +1.7% |
| Cash & short-term investments | $532.73M | $476.30M | $467.01M | $506.51M | $606.02M | +11.8% |
| Total current assets | $573.74M | $522.99M | $514.08M | $545.68M | $735.71M | +9.7% |
| Property, plant & equipment | $109.82M | $113.92M | $117.72M | $121.76M | $125.65M | -3.6% |
| Goodwill & intangibles | $24.64M | $24.71M | $24.79M | $24.86M | $24.93M | -0.3% |
| Total assets | $1.21B | $1.03B | $1.00B | $1.02B | $1.19B | +18.5% |
| Total current liabilities | $94.96M | $73.56M | $92.81M | $75.22M | $105.00M | +29.1% |
| Total debt | $93.27M | $95.58M | $97.85M | $100.17M | $102.23M | -2.4% |
| Total liabilities | $232.31M | $212.82M | $237.55M | $223.35M | $245.06M | +9.2% |
| Retained earnings | -$1.24B | -$1.32B | -$1.20B | -$1.15B | -$991.71M | +6.1% |
| Shareholder equity | $982.49M | $812.76M | $765.28M | $796.10M | $947.47M | +20.9% |
| Working capital | $478.78M | $449.43M | $421.26M | $470.46M | $630.70M | +6.5% |
| Net tangible assets | $957.85M | $788.05M | $740.49M | $771.24M | $922.54M | +21.5% |
| Shares issued | 169.19M | 161.23M | 139.47M | 139.02M | 138.89M | +4.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $80.08M | -$125.69M | -$42.92M | -$163.14M | -$110.96M | +163.7% |
| Depreciation & amortisation | $2.80M | $2.81M | $2.90M | $3.00M | $2.92M | -0.3% |
| Stock-based compensation | $12.39M | $12.09M | $11.21M | $11.36M | $12.45M | +2.5% |
| Change in working capital | $23.47M | -$22.68M | -$2.84M | -$20.60M | -$25.06M | +203.5% |
| Operating cash flow | $123.33M | -$132.39M | -$25.88M | -$167.57M | -$120.22M | +193.2% |
| Capital expenditure | -$32.00K | -$390.00K | -$348.00K | -$317.00K | -$2.54M | +91.8% |
| Investing cash flow | -$197.14M | $11.84M | $86.65M | $40.45M | $56.46M | -1,765.8% |
| Financing cash flow | $78.38M | $162.52M | $1.04M | $102.00K | $2.05M | -51.8% |
| Free cash flow | $123.29M | -$132.78M | -$26.22M | -$167.89M | -$122.76M | +192.9% |
| End cash position | $287.60M | $283.04M | $241.07M | $179.26M | $306.28M | +1.6% |
Options analytics
Put / call volume
0.29
Call-heavy session
Put / call open interest
1.83
Positioning, not flow
Max pain
5.00
-56.9% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
106
Contracts, this expiry
Put volume
31
Contracts, this expiry
Heaviest call OI
16.00
7 contracts
Heaviest put OI
5.00
16 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.90 | 0.47 | -47.5% |
| Mar 2026 | 0.48 | -0.85 | -276.6% |
| Dec 2025 | -0.45 | -0.31 | +31.6% |
| Sep 2025 | -0.86 | -1.17 | -36.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.73 | 7 | $987.29K | +311.4% |
| Next quarter | -0.63 | 7 | $6.30M | -90.2% |
| Current year | -1.76 | 7 | $245.20M | +257.7% |
| Next year | -2.49 | 7 | $76.09M | -69.0% |
Analyst targets & ownership
Mean target$20.78
High target$30.00
Low target$15.00
Implied upside79.12%
Analyst count9
ConsensusSTRONG BUY
Strong buy / Buy3 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders6.57%
Held by institutions84.36%
Institutions holding335
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.07
+4.84% from price
SMA 20
10.91
+6.28% from price
SMA 50
10.25
+13.13% from price
SMA 100
9.78
+18.59% from price
SMA 200
9.08
+27.80% from price
EMA 12
11.15
+4.01% from price
EMA 26
10.88
+6.61% from price
EMA 50
10.50
+10.43% from price
RSI (14)
60.4
Neutral
MACD (12,26,9)
0.27
Hist 0.04
ATR (14)
0.64
5.52% of price
Realised vol 30D
50.5%
Annualised
Bollinger upper
11.68
20, 2σ
Bollinger lower
10.15
20, 2σ
50 / 200 cross
Golden
10.25 vs 9.08
Trend bias
Above 200
+27.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.73
More volatile than market
Correlation to SPY
0.35
Loosely linked
Realised vol 30D
50.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-25.6%
Peak to trough
Max drawdown 5Y
-92.1%
Peak to trough
ATR 14
0.64
5.52% of price
Beta (reported)
1.59
5Y monthly, from filing
Short interest
Shares short
19.66M
Prior 19.60M
Change vs prior
+0.3%
Shorts adding
% of float
11.76%
Elevated
% of shares out
11.62%
Against total outstanding
Days to cover
9.7
Crowded exit
Float
129.82M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 11, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jun 3, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Mar 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 25, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Feb 24, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Feb 24, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Feb 24, 26 | Needham | MAINTAINED | Buy | Buy |
| Feb 9, 26 | Needham | MAINTAINED | Buy | Buy |
| Dec 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 3, 25 | Evercore ISI Group | INITIATED | — | Outperform |
| Aug 27, 25 | B of A Securities | UPGRADE | Neutral | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-01
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-24
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-28
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEFA14A · 2026-04-16
Headlines
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Business Wire · 2d ago
Vir Biotechnology Names Aziz Sawaf as CFO
MT Newswires · 6d ago
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Business Wire · 6d ago
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire · 37d ago
Olema Pharmaceuticals Names Jason O'Byrne CFO
MT Newswires · 55d ago
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
Motley Fool · 55d ago
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary
Moby · 62d ago
Vir Biotechnology Q2 Earnings Call Highlights
MarketBeat · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.